Heron Therapeutics, Inc. reiterated net product sales guidance for the full year 2023. The company is reiterating full-year 2023 net product sales guidance for the oncology care franchise of $99 million to $103 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.505 USD | +7.05% | -1.96% | +47.06% |
Apr. 23 | Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target | MT |
Mar. 21 | Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.06% | 352M | |
+28.17% | 42.68B | |
-3.06% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+7.13% | 24.94B | |
-21.01% | 18.96B | |
+28.71% | 12.3B | |
-2.39% | 11.95B | |
-1.85% | 11.55B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Reiterates Net Product Sales Guidance for the Full Year 2023